
|Articles|April 13, 2021
New Therapeutic Targets in Non–Small Cell Lung Cancer: KRAS G12C
On February 3, 2021, OncLive® brought together a group of oncologists who specialize in the treatment of lung cancer to participate in a virtual workshop to discuss the emerging treatment landscape of targeted therapies in NSCLC. This article summarizes key data about KRAS G12C as a therapeutic target as well as insights from stakeholder discussions regarding this topic.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Emerging Data With Oral SERDs Reframe Frontline and Post–CDK4/6 Decisions in ER+ Breast Cancer
2
Relacorilant Plus Nab-Paclitaxel Meets OS End Point of ROSELLA Trial in PROC
3
Sofi-Cel Earns FDA Breakthrough Therapy Designation in Heavily Pretreated R/R T-ALL and T-LBL
4
Treatment Individualization Is Increasingly Vital With T-DXd Poised to Enter Early-Stage HER2+ Breast Cancer Paradigm
5



























































































